The Cost of Cancer Care is Not Related to Its Outcomes

Overview

Journal Ecancermedicalscience

Specialty Oncology

Date 2016 Dec 21

PMID 27994643

Citations 1

Authors

Guy Storme

S Dhaese

D Corens

Mark De Ridder

Affiliations

Soon will be listed here.

Abstract

Solid tumours make up 90% of all proliferative diseases and the main action for cure remains surgery, removing the visible tumour as well as the surrounding tissue. Radiotherapy is an added value for eliminating local microscopic as well as regional disease. Systemic treatment has a small impact on the outcome but has a cost, which is as much as all the other actions such as diagnostic tools and treatments.

Citing Articles

Is there any benefit to particles over photon radiotherapy?.

Goossens M, Van Den Bulcke M, Gevaert T, Meheus L, Verellen D, Cosset J Ecancermedicalscience. 2020; 13:982.

PMID: 32010206 PMC: 6974365. DOI: 10.3332/ecancer.2019.982.

References

Prasad V, Vandross A . Characteristics of Exceptional or Super Responders to Cancer Drugs. Mayo Clin Proc. 2015; 90(12):1639-49. DOI: 10.1016/j.mayocp.2015.08.017. View

Prasad V . Perspective: The precision-oncology illusion. Nature. 2016; 537(7619):S63. DOI: 10.1038/537S63a. View

Saltz L . The Value of Considering Cost, and the Cost of Not Considering Value. J Clin Oncol. 2015; 34(7):659-60. PMC: 5569684. DOI: 10.1200/JCO.2015.64.7867. View

Fonteyne V, Soete G, Arcangeli S, De Neve W, Rappe B, Storme G . Hypofractionated high-dose radiation therapy for prostate cancer: long-term results of a multi-institutional phase II trial. Int J Radiat Oncol Biol Phys. 2012; 84(4):e483-90. DOI: 10.1016/j.ijrobp.2012.04.012. View

Voordeckers M, Vinh-Hung V, Lamote J, Bretz A, Storme G . Survival benefit with radiation therapy in node-positive breast carcinoma patients. Strahlenther Onkol. 2009; 185(10):656-62. DOI: 10.1007/s00066-009-2047-z. View

Hodi F, Chesney J, Pavlick A, Robert C, Grossmann K, Mcdermott D . Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol. 2016; 17(11):1558-1568. PMC: 5630525. DOI: 10.1016/S1470-2045(16)30366-7. View

Morgan G, Ward R, Barton M . The contribution of cytotoxic chemotherapy to 5-year survival in adult malignancies. Clin Oncol (R Coll Radiol). 2005; 16(8):549-60. DOI: 10.1016/j.clon.2004.06.007. View

Le Tourneau C, Delord J, Goncalves A, Gavoille C, Dubot C, Isambert N . Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncol. 2015; 16(13):1324-34. DOI: 10.1016/S1470-2045(15)00188-6. View

Bartelink H, Maingon P, Poortmans P, Weltens C, Fourquet A, Jager J . Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial. Lancet Oncol. 2014; 16(1):47-56. DOI: 10.1016/S1470-2045(14)71156-8. View

10.

Sullivan R, Peppercorn J, Sikora K, Zalcberg J, Meropol N, Amir E . Delivering affordable cancer care in high-income countries. Lancet Oncol. 2011; 12(10):933-80. DOI: 10.1016/S1470-2045(11)70141-3. View

11.

Van den Begin R, Engels B, Gevaert T, Duchateau M, Tournel K, Verellen D . Impact of inadequate respiratory motion management in SBRT for oligometastatic colorectal cancer. Radiother Oncol. 2014; 113(2):235-9. DOI: 10.1016/j.radonc.2014.11.005. View

12.

Voordeckers M, Vinh-Hung V, Van De Steene J, Lamote J, Storme G . The lymph node ratio as prognostic factor in node-positive breast cancer. Radiother Oncol. 2004; 70(3):225-30. DOI: 10.1016/j.radonc.2003.10.015. View

13.

Voordeckers M, Farrag A, Everaert H, Tournel K, Storme G, Verellen D . Parotid gland sparing with helical tomotherapy in head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2012; 84(2):443-8. DOI: 10.1016/j.ijrobp.2011.11.070. View

14.

Engels B, Tournel K, Everaert H, Hoorens A, Sermeus A, Christian N . Phase II study of preoperative helical tomotherapy with a simultaneous integrated boost for rectal cancer. Int J Radiat Oncol Biol Phys. 2011; 83(1):142-8. DOI: 10.1016/j.ijrobp.2011.05.068. View

15.

Bolla M, Gonzalez D, Warde P, Dubois J, Mirimanoff R, Storme G . Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med. 1997; 337(5):295-300. DOI: 10.1056/NEJM199707313370502. View

16.

Bral S, Duchateau M, Versmessen H, Engels B, Tournel K, Vinh-Hung V . Toxicity and outcome results of a class solution with moderately hypofractionated radiotherapy in inoperable Stage III non-small cell lung cancer using helical tomotherapy. Int J Radiat Oncol Biol Phys. 2010; 77(5):1352-9. DOI: 10.1016/j.ijrobp.2009.06.075. View